Shares of BeyondSpring skyrocket on new, positive cancer drug trial results
Sometimes results come along that shock even a biotech’s believers.
On Wednesday, BeyondSpring, a small New York biotech with an offbeat approach to immunotherapy, announced its lead drug significantly extended non-small cell lung cancer patients’ lives in a large trial. Although the company did not release the exact survival data, it said that nearly twice as many patients were alive after two years on the drug arm than on the standard-of-care arm.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 117,800+ biopharma pros reading Endpoints daily — and it's free.